Professional Documents
Culture Documents
Metabical: Pricing, Packaging and Demand Forecasting
Metabical: Pricing, Packaging and Demand Forecasting
In April 2008, after 10 years of testing and $400 million in Research and Development costs, Cambridge Sciences
Pharmaceuticals prescription drug Metabical was about to receive its FDA approval
Approved for use by only those people looking to shed weight between 10 to 30 pounds
Barbara Printup was in charge of managing upcoming January 2009 launch of Metabical in the United States
Printup had to made several critical decision to decide the Optimal Package size for the drug
Establish initial Demanding Forecast for the production in the first 5 years
Decide the Pricing Model from the three initial model and ensure that the desired ROI(minimum 5% within 5
years) of the company is met
Two categories of Prescription Diet drugs, appetite suppressants and
fat absorbing blockers
Competitive kidney stones, severe stomach pain and gall bladder disease
Because of this it was prescribed for use only by obese and severely
Landscape
obese (BMI>=30)
Over the counter drug Alli was approved by FDA for weight loss use
(but over 30 reports of liver damage were being reviewed)